Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4291164 | 0.99 | LTA4H (0.55) | LTA4HSIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL3492112 | 0.84 | LTA4H (0.56) | LTA4HSIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8113187 | 0.84 | LTA4H (0.55) | LTA4HSIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24803467 | 0.82 | LTA4H (0.57) | LTA4HSIGMAR1DRD2CYP1A2CYP3A4 | |
| SCHEMBL13308369 | 0.82 | LTA4H (0.57) | LTA4HSIGMAR1DRD2CYP1A2CYP3A4 | |
| SCHEMBL3495379 | 0.79 | LTA4H (0.59) | LTA4HSIGMAR1DRD2CYP1A2CYP3A4 | |
| SCHEMBL1875436 | 0.78 | LTA4H (0.65) | LTA4HSIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1875435 | 0.78 | LTA4H (0.65) | LTA4HSIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2873528 | 0.78 | LTA4H (0.65) | LTA4HSIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10219060 | 0.78 | LTA4H (0.57) | LTA4HSIGMAR1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885SIGMAR1 3163/4885HTR2A 4298/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885SIGMAR1 3163/4885HTR2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.